You are here: Home » 
  1. News

| CAN-SHOCK starts into the next phase!

Another important milestone has been achieved, allowing the Institute for Myocardial Infarction Research to generate new data to understand the efficacy and safety of cangrelor in high-risk patients.

Now that the first study sites have been initiated, we can start collecting clinical data. Data on the use of cangrelor in high-risk patients with acute myocardial infarction and PCI who have experienced CPR, cardiogenic shock or received mechanical or non-invasive ventilation will be collected from pre-existing clinical documentation and systematically analyzed. The register trial has also been extended to include clinical trial sites in Austria in order to be able to generate a significant number of patient outcomes. The goal is to generate clinical data from approximately 450 consecutive patients within the next six months.


We would like to get to know you and your ideas.

Start project

Consent to the use of cookies

In order to make our website more appealing to visitors and to enable the use of certain functions, we use cookies on various pages. By continuing to use the website, you consent to the use of cookies. Find out more.

I agree
Scroll to top